Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
TO THE EDITOR:

Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion

Xinyi Xia,1,3,* Kening Li,4,5,* Lingxiang Wu,4,5,* Zhihua Wang,2,3,6,* Mengyan Zhu,4,5 Bin Huang,4,5 Jie Li,4,5 Ziyu Wang,4,5 Wei Wu,4,5 Min Wu,4,5 Wanlin Li,4,5 Lu Li,4,5 Yun Cai,4,5 Bakwatanisa Bosco,4,5 Aifang Zhong,2,7 Xiong Liu,3,8 Tangfeng Lv,3,9,10 Zhenhua Gan,3,9
Guang Chen,10,11 Yunhu Pan,10,12 Caidong Liu,13 Kai Zhang,13 Xiaoli Xu,3,9,10 Changjun Wang,3,8 and Qianghu Wang4,5,14

1COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China; 2Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, China; 3Joint Expert Group for COVID-19, Wuhan Huoshenshan Hospital, Wuhan, China; 4Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; 5Department of Bioinformatics, Nanjing Medical University, Nanjing, China; 6Department of Laboratory Medicine & Blood Transfusion, the 907th Hospital, Nanping, China; 7Medical Technical Support Division, the 904th Hospital, Changzhou, China; 8Center for Disease Control and Prevention of PLA, Beijing, China; 9Jinling Hospital, Nanjing University School of Medicine, Nanjing, China; 10Department of Infectious Disease, Wuhan Huoshenshan Hospital, Wuhan, China; 11Department of Respiratory Disease, the 907th Hospital, Nanping, China; 12Intensive Care Unit, the 907th Hospital, Nanping, China; 13General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; and 14Biomedical Big Data Center, Nanjing Medical University, Nanjing, China

COVID-19 has spread to >210 countries and territories worldwide.1–4 Although some agents are under investigation, there are no targeted drugs that could effectively eliminate or treat the novel virus.5,6 Treatments for patients with COVID-19 are urgently needed, especially for severe or critical cases. COVID-19 convalescent plasma (CCP) therapy involves the administration of plasma from patients who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infections.7,8 Although several case series and an open-label trial regarding CCP for patients with COVID-19 were previously reported,9–12 the effectiveness and safety of CCP have still not been comprehensively evaluated in large retrospective cohorts or randomized blinded trials. Herein, we present the results of 1568 patients with severe or critical COVID-19, including 1430 patients who received standard treatment only and 138 patients who also received ABO-compatible CCP, in Wuhan Huoshenshan Hospital (China), admitted from 4 February 2020 to 30 March 2020.

The clinical characteristics of patients were compared between the CCP group and the standard treatment group (Table 1). According to the clinical status and body weight of each recipient, 200 to 1200 mL of CCP was transfused (supplemental Methods, available on the Blood Web site; supplemental Figure 1). A 6-category scale score (SCSS) was used to evaluate the clinical status. Despite the higher severity level, only 3 patients (2.2%) died in the CCP group up to April 20, reducing ~50% of the mortality rate compared with that in the standard treatment group (4.1%). Notably, for the 126 non-ICU patients before CCP therapy, 3 patients (2.4%) were admitted to the ICU, compared with 72 (5.1%) of 1403 ICU admissions in the standard treatment group.

We analyzed the dynamic changes in the SARS-CoV-2 viral load of nasopharyngeal swabs, anti–SARS-CoV-2 antibody levels, and various types of laboratory and radiologic parameters before and after CCP therapy. Within 14 days following CCP therapy, 20 (80%) of the 25 patients who were positive for SARS-CoV-2 became virus free (Figure 1A). The levels of the spike (S)- and receptor binding domain (RBD)-specific immunoglobulin G (IgG) increased within 3 days, which then slightly decreased within 3 to 7 days after CCP therapy. However, nucleoprotein (N)-specific antibody levels did not increase after CCP therapy (Figure 1B). According to a previous study, S- and RBD-specific IgGs play an important role in neutralizing viruses,13 indicating that the immediate increase in S- and RBD-specific IgG was one of the reasons for CCP efficacy. Moreover, antibody levels in the CCP units positively correlated with the antibody changes in recipients (r = 0.4; P = .02) (supplemental Figure 2A). In addition, the percentage of lymphocytes significantly increased within 3 days (P = .0009) and was maintained at a relatively high level within 21 days after CCP therapy, whereas the neutrophil percentage significantly decreased. The concentration of C-reactive protein decreased after CCP therapy (Figure 1C–F), indicating the anti-inflammatory effect of CCP.14 Moreover, 77.9% of cases represented lung lesion absorption within 14 days after CCP therapy (Figure 1G).

To investigate the safety of CCP, cardiac, liver, and renal functions were assessed by analyzing the results of routine blood and biochemistry examinations (supplemental Table 1). None of these indexes showed significant differences before and after CCP therapy, except for the decrease in total bilirubin levels. In addition, levels of cytokines such as tumor necrosis factor-α, interleukin-10, and interleukin-6 were compared before and after CCP therapy. The results showed that all of these cytokines remained at the original level. In addition, 3 patients had minor allergic reactions (pruritus or erythema) during the transfusion, but no severe transfusion reactions such as transfusion-associated circulatory overload, transfusion-related acute lung injury, or severe allergic reactions were observed. Along with results of recent reports,15 the low rate of serious adverse events is reassuring.

We classified patients treated with CCP as responders, partial responders, and nonresponders according to the SCSS (supplemental Methods) and investigated the differences in various
laboratory parameters between these groups before CCP therapy (supplemental Table 2). The lymphocyte percentage was significantly higher in responders (20.1%, 11.9%, and 6.8% in responders, partial responders, and nonresponders, respectively; \( P < .001 \)), whereas the neutrophil percentage was significantly lower in responders before CCP therapy (\( P < .01 \)). The level of

| Characteristic | Total (N = 1568) | CCP (n = 138) | Standard treatment (n = 1430) | \( P \) |
|----------------|------------------|---------------|-------------------------------|------|
| Age, median (IQR), y | 63 (54-71) | 65 (57-73) | 63 (53-71) | .008 |
| Sex, no. (%) | | | | .3 |
| Female | 771 (49.2) | 61 (44.2) | 710 (49.7) |  — |
| Male | 797 (50.8) | 77 (55.8) | 720 (50.3) |  — |
| Comorbidity, no. (%) | | | | |
| Hypertension | 565 (36.0) | 53 (38.4) | 508 (35.5) | .5 |
| Diabetes | 252 (16.1) | 31 (22.5) | 218 (15.2) | .04 |
| Cardiovascular disease | 239 (15.2) | 27 (19.6) | 210 (14.7) | .1 |
| Cerebrovascular disease | 89 (5.7) | 12 (8.7) | 75 (5.2) | .1 |
| Malignancy | 61 (3.9) | 4 (2.9) | 53 (3.7) | .8 |
| Chronic obstructive pulmonary disease | 105 (6.7) | 12 (8.7) | 91 (6.4) | .3 |
| Chronic renal disease | 37 (2.4) | 4 (2.8) | 33 (2.3) | .6 |
| Chronic liver disease | 44 (2.8) | 4 (2.9) | 39 (2.7) | .8 |
| Immunodeficiency | 6 (0.4) | 2 (1.4) | 4 (0.28) | .09 |
| Symptoms, no. (%) | | | | |
| Fatigue | 625 (39.9) | 57 (41.3) | 564 (39.4) | .7 |
| Fever | 1080 (68.9) | 93 (67.4) | 984 (68.8) | .8 |
| Cough | 952 (60.7) | 83 (60.1) | 863 (60.3) | 1 |
| Shortness of breath | 181 (11.5) | 28 (20.3) | 150 (10.5) | .001 |
| Chest congestion | 200 (12.8) | 24 (17.4) | 175 (12.2) | .1 |
| Nausea or vomiting | 16 (1.0) | 2 (1.4) | 13 (0.9) | .4 |
| Diarrhea | 43 (2.7) | 4 (2.9) | 39 (2.7) | .8 |
| Highest temperature, median (IQR), °C | 37.1 (36.9-37.4) | 37.2 (37.0-37.4) | 37.1 (36.9-37.3) | .008 |
| Days from symptoms onset to admission, median (IQR) | 25 (14-35) | 35 (18-40) | 25 (14-35) | <.001 |
| Days from admission to discharge, median (IQR) | 14 (8-22) | 22 (16-30) | 14 (8-21) | <.001 |
| Days from symptoms onset to CCP therapy, median (IQR) | — | 45 (39-54) | — | — |
| Degree of severity, no. (%) | | | | .009 |
| Severe | 1420 (90.6) | 116 (84.1) | 1304 (91.2) | |
| Critical | 148 (9.4) | 22 (15.9) | 126 (8.8) | |
| Highest SCSS during hospitalization, no. (%) | | | | .04 |
| 2: Hospitalized, not requiring oxygen | 730 (46.6) | 55 (39.9) | 675 (50.4) | — |
| 3: Low-flow oxygen therapy | 519 (33.1) | 50 (36.2) | 469 (35.0) | — |
| 4: High-flow oxygen therapy or noninvasive mechanical ventilation | 252 (16.1) | 28 (20.3) | 224 (16.7) | — |
| 5: ECMO or invasive mechanical ventilation | 5 (0.3) | 2 (1.4) | 3 (0.2) | — |
| ICU admission, no. (%) | 75 (4.9) | 3 (2.4) | 72 (5.1) | .2 |
| Clinical outcomes, no. (%) | | | | <.001 |
| Discharge from hospital | 1487 (94.8) | 121 (87.7) | 1366 (95.5) | — |
| Death | 62 (4.0) | 3 (2.2) | 59 (4.1) | — |
| Hospitalization | 19 (1.2) | 14 (10.1) | 5 (0.3) | — |

P values marked in bold indicate the significant differences between CCP and standard treatment groups.
ECMO, extracorporeal membrane oxygenation; IQR, interquartile range.
C-reactive protein was significantly higher in nonresponders (5.2, 25.9, and 73.1 mg/L in responders, partial responders, and nonresponders; \( P < .01 \)), indicating that the strong inflammatory reaction was associated with an insensible response to CCP. In addition, the levels of lactate dehydrogenase, B-type natriuretic peptide, urea nitrogen, procalcitonin, and glucose were markedly higher in nonresponders than in responders before CCP therapy \( ( P < .05 ) \), suggesting that abnormal metabolic functions had an effect on CCP response. Although not significant, the antibody levels in CCP units, which were transfused into rapid
responders, were higher than those in moderate responders (supplemental Figure 2B). These preliminary results suggest that CCP units with high antibody levels could confer immediate immunity to recipients, and the efficacy of CCP for responders depends on the antibody levels of the donor plasma.

Patients with an SCSS of 5 before therapy showed no improvements after CCP therapy. However, within 7 days after CCP therapy, 66.7% and 83.4% of patients with an SCSS of 4 or 3, respectively, exhibited various degrees of clinical improvement (Figure 1H). This result indicates that CCP could effectively improve the respiratory symptoms of patients with severe disease and help them in being weaned from oxygen support. However, patients who were extremely critically ill could not benefit from CCP, which is consistent with the findings of studies by Li et al.12 and Liu et al.16 which showed that intubated or patients with life-threatening COVID-19 were not likely to benefit from CCP.

Experience from SARS-CoV-1 shows that convalescent plasma is most effective when administered shortly after symptom onset, typically within 2 weeks.7,14,17 The study by Liu et al16 showed that the effect of CCP was similar in an interval of 3 weeks’ duration of symptoms. We compared the time to clinical improvement in patients with different therapy timings in our cohort, including 1 to 4 weeks, 5 to 6 weeks, 7 weeks, and ≥8 weeks after symptom onset. The results showed that the median time to clinical improvement was ~10 days in the 1 to 4 weeks’, 5 to 6 weeks’, and 7 weeks’ groups. However, the time to clinical improvement was significantly prolonged in the ≥8 weeks’ group (Figure 1I).

In summary, we analyzed a large cohort of patients with COVID-19 who received CCP and provide detailed evidence regarding their clinical improvement. Although the homogeneous data obtained from a single center may reduce some biases, there could inevitably be some confounding factors (eg, biased patient assignments) in this retrospective study. In addition, complete data on neutralizing antibody titers in CCP units were not available, limiting the power of evaluating the correlation between the quality of donor plasma and efficacy. Moreover, a stratified analysis of cases of severe and critical patients could not be performed due to the low proportion of critical patients. This analysis differs from existing studies in that its dynamic laboratory observations using large-scale data make it possible to analyze the potential therapeutic mechanism of CCP, recognize the characteristics of responders and nonresponders, and identify the indications and timing of therapy.18 Our results suggest that CCP, transfused even after 2 weeks (median of 45 days in our cohort) of symptom onset, could improve the symptoms and mortality in patients with severe or critical cases of COVID-19. We anticipate that this study could shed new light in clinical practice and monoclonal antibody development for COVID-19.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (grants 81572893, 81972358, and 81959113), the Key Foundation of Wuhan Huoshenshan Hospital (grant 2020[18]), the Key Research & Development Program of Jiangsu Province (grants BE2017733 and BE2018713), the Medical Innovation Project of Logistics Service (grant 18JS005), and the Basic Research Program of Jiangsu Province (grant BK20180036).

Authorship

Contribution: Q.W., C.W., and X. Xu had full access to all of the data in the study; take responsibility for the integrity of the data and the accuracy of the data analysis, and were responsible for concept and design; X. Xia, Zhihua Wang, A.Z., X.L., T.L., Z.G., G.C., and Y.P. performed data collection; K.L., L.W., M.Z., B.H., J.L., Ziyu Wang, W.W., L.L., Y.C., M.W., W.L., C.L., and K.Z. contributed to data analysis and interpretation; and K.L., L.W., and B.B. drafted the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: M.Z., 0000-0003-2953-8309; B.B., 0000-0001-5007-0240; Q.W., 0000-0002-3488-1059.

Correspondence: Xiaoli Xu, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Rd, Nanjing 210002, China, e-mail: xlix2019t@siina.com; Changjun Wang, Center for Disease Control and Prevention of PLA, 20 Dongdaje St, Beijing 100071, China, e-mail: science@hotmail.com; and Qianghu Wang, Center for Global Health, School of Public Health, Nanjing Medical University, 818 Tianyuan East Rd, Nanjing 211100, China, e-mail: wangqgh@njmu.edu.cn.

Footnotes

*X. Xia, K.L., L.W., and Zhihua Wang contributed equally to this article.

For original data, please contact Qianghu Wang, wangqgh@njmu.edu.cn.

The online version of this article contains a data supplement.

There is a Blood Commentary on this article in this issue.

REFERENCES

1. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.

2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239.

3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.

4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.

5. World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 9 June 2020.

6. Lu H. Drug treatment options for the 2019 coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71.

7. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-1548.

8. Garneaud O, Heshmati F, Pozzetto B, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23(1):39-44.

9. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582.

10. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-9496.

11. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China (published online ahead of print 15 April 2020). J Med Virol. doi:10.1002/jmv.25882.

12. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. Blood. 2020;136(6):758-764.

13. Liang W, Guo R, Chen W, et al. Epidemiological characteristics of 222 coronavirus disease 2019 (COVID-19) cases in Wuhan City, China. Proc Natl Acad Sci U S A. 2020;117(17):9464-9469.

14. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.

15. World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 9 June 2020.

16. Lu H. Drug treatment options for the 2019 coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71.

17. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-1548.

18. Garneaud O, Heshmati F, Pozzetto B, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23(1):39-44.

19. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582.

20. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-9496.

21. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China (published online ahead of print 15 April 2020). J Med Virol. doi:10.1002/jmv.25882.

22. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. Blood. 2020;136(6):758-764.

23. Liang W, Guo R, Chen W, et al. Epidemiological characteristics of 222 coronavirus disease 2019 (COVID-19) cases in Wuhan City, China. Proc Natl Acad Sci U S A. 2020;117(17):9464-9469.
Use of convalescent plasma in hospitalized patients with COVID-19: case series

Livia Hegerova,1 Ted A. Gooley,2 Kelly A. Sweerus,3 Cynthia Maree,4 Neil Bailey,1 Megumi Bailey,1 Vanessa Dunleavy,1 Krish Patel,1 Kirsten Alcorn,1 Rebecca Haley,1 Jill M. Johnsen,5,6 Barbara A. Konkle,5,6 Annamarie C. Lahti,7 Morgan L. Alexander,7 Jason D. Goldman,4 Anne Lipke,3 Sun-jung Lim,3 Mark D. Sullivan,3 John S. Pauk,4 and John M. Pagel1

1Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA; 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 3Division of Pulmonary and Critical Care and 4Division of Infectious Disease, Department of Internal Medicine, Swedish Medical Center, Seattle, WA; 5Bloodworks Northwest, Seattle, WA; 6Division of Hematology, University of Washington, Seattle, WA; and 7Neuroscience Institute, Swedish Medical Center, Seattle, WA

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily manifests as a respiratory illness and has affected >5 million people worldwide, with >350,000 deaths.1,2 There are no current approved therapies for COVID-19. Administration of convalescent plasma (CP) may be effective therapy for COVID-19.3-6 Early indicators suggest that transfusion of CP is safe in COVID-19.7 We report the early clinical experience of 20 hospitalized patients treated with CP compared with 20 matched controls with severe or life-threatening COVID-19 infection.

Twenty patients with COVID-19 infection, diagnosed using quantitative reverse-transcriptase polymerase chain reaction assay for SARS-CoV-2 on nasopharyngeal swabs, were treated with CP in 5 hospitals in the Seattle area between April 13 and April 26 of 2020. Patients with severe or critical illness were treated with 1 unit of ABO-compatible CP under an expanded access protocol (IND 19832). Baseline demographic and clinical characteristics, including comorbidities, severity of illness, laboratory parameters, and clinical outcomes, were recorded up to 14 days after CP transfusion or the equivalent day of hospitalization for controls. Donor information was also collected. This study was approved by the Institutional Review Board of Providence St. Joseph Health.

The median age of patients treated with CP was 60 years (range, 29-95), with 20% of patients older than 80 years. The most common signs and symptoms of COVID-19 illness were cough or shortness of breath (90%), lymphopenia (67%), and an abnormal radiograph (80%). The most common comorbidities were hypertension (60%), diabetes (45%), and obesity (20%). One third of patients required mechanical ventilation (MV). Median time from hospitalization to CP was early at 2 days (interquartile range [IQR], 1-4.3). The majority of patients received additional therapies, including azithromycin (60%), hydroxychloroquine (55%), or multiple combinations. CP recipients had primarily A (45%) or B (45%) ABO type.

The 8 COVID-19–recovered donors who provided units ranged in age from 29 to 79 years. All had symptoms of respiratory illness, muscle aches, and/or headache, but none required hospitalization. All were more >28 days past their last symptoms of COVID illness. Donations were well tolerated and without significant complications. Anti–SARS-CoV-2 immunoglobulin G serology, as determined by the Abbott ARCHITECT, was positive in all but 1 donor, whereas Eurolmmun was negative (n = 1), equivocal (n = 3), moderate positive (n = 3), or high positive (n = 1).

Figure 1 shows the clinical and laboratory parameters reported over 7 days after CP. Temperature improved in all patients after delivery of CP. The mean temperature decrease was 0.3°C in the CP group (standard deviation [SD], 0.5), whereas mean absolute lymphocyte count was 1.01 × 10⁹/µL (SD, 0.47) and did not change by day 7 (1.09 × 10⁹/µL; SD, 0.55). The mean baseline C-reactive protein was 170.5 mg/L (SD, 137.6), which decreased to 127.5 mg/L (SD, 144.0) after CP. A decrease in the fraction of inspired oxygen (FiO₂) from 53% (SD, 29) to 47% (SD, 24) was seen by day 7 after CP. For patients who were on MV, the mean Pao₂/FiO₂ of inspired oxygen ratio at baseline was 81 (SD, 25), which improved to 96 (SD, 22). Two patients were liberated from the ventilator, whereas 2 required intubation after CP.

The outcomes of all patients are reported in Table 1. Median World Health Organization (WHO) ordinal scale score was 5 at CP infusion, which improved to 4.5 at day 7 and 3.5 at day 14. No adverse events with CP were reported. The incidence of venous thromboembolism (VTE) was (20%). At 7 days of follow-up, 25% of patients were discharged, whereas 10% had died.